Opinions
Laura Wallace
Barr Laboratories
BRL-N
PAST TOP PICK
May 17, 2006
(A Top Pick Mar 15/06. Down 22%.) Lowered its guidance by $0.01 and also received a letter from the FDA denying them an extension on a patent. Feels they can continue to grow earnings in the 15/20% range. In a good buying range now.
$49.730
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
A generic manufacturer, so unlike big pharmas that suffer when things come off, they actually benefit. Just picked up Allegra which is coming off patent. A great growth vehicle with a lot of drugs coming off patent in the next several years. Great exposure in women's health products.
biotechnology
pharmaceutical
TOP PICK
Generic drug manufacturer. Earnings are growing in the 20/25% range. Generics are the beneficiaries of the push to control the accelerating healthcare costs in the US. Have a good record of acquiring new generics and delivering them in a very cost effective way. No debt on the balance sheet. Great operating margins in the 35/38% range.
biotechnology
pharmaceutical